Effect of Primary Tumor Volume on Survival of Concurrent Chemoradiotherapy in Stage IV Non-small Cell Lung Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Sep 16

PMID 39279741

Authors

Xiaxia Chen

Wei Zhang

Lan Luo

Shimei Fu

Dongdong Cao

Shengfa Su

Qingsong Li

Wengang Yang

Yichao Geng

Bing Lu

Weiwei Ouyang

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the survival effect of thoracic gross tumor volume (GTV) in three-dimensional (3D) radiotherapy for stage IV non-small cell lung cancer (NSCLC).

Methods: The data cases were obtained from a single-center retrospective analysis. From May. From 2008 to August 2018, 377 treatment criteria were enrolled. GTV was defined as the volume of the primary lesion and the hilus as well as the mediastinal metastatic lymph node. Chemotherapy was a platinum-based combined regimen of two drugs. The number of median chemotherapy cycles was 4 (2-6), and the cut-off value of the planning target volume (PTV) dose of the primary tumor was 63 Gy (30-76.5 Gy). The cut-off value of GTV volume was 150 cm (5.83-3535.20 cm).

Results: The survival rate of patients with GTV <150 cm is better than patients with GTV ≥150 cm. Multivariate Cox regression analyses suggested that peripheral lung cancer, radiation dose ≥63 Gy, GTV <150 cm, 4-6 cycles of chemotherapy, and CR + PR are good prognostic factors for patients with stage IV non-small cell lung cancer. The survival rate of patients with GTV <150 cm was longer than patients with ≥150 cm when they underwent 2 to 3 cycles of chemotherapy concurrent 3D radiotherapy (p < 0.05). When performing 4 to 6 cycles of chemotherapy concurrent 3D radiotherapy, there was no significant difference between <150 cm and ≥150 cm.

Conclusions: The volume of stage IV NSCLC primary tumor can affect the survival of patients. Appropriate treatment methods can be opted by considering the volume of tumors to extend patients' lifetime to the utmost.

Citing Articles

Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non-small cell lung cancer.

Chen X, Zhang W, Luo L, Fu S, Cao D, Su S Cancer Med. 2024; 13(17):e70221.

PMID: 39279741 PMC: 11403300. DOI: 10.1002/cam4.70221.

References

Bradley J, Ieumwananonthachai N, Purdy J, Wasserman T, Lockett M, Graham M . Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002; 52(1):49-57. DOI: 10.1016/s0360-3016(01)01772-2. View

Park S, Ahn B, Lim S, Sun J, Kim H, Hong M . Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. J Thorac Oncol. 2018; 13(9):1373-1382. DOI: 10.1016/j.jtho.2018.05.026. View

Kramer G, Wanders S, Noordijk E, Vonk E, van Houwelingen H, van den Hout W . Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol. 2005; 23(13):2962-70. DOI: 10.1200/JCO.2005.01.685. View

Su S, Li M, Geng Y, Yang W, Ma Z, Li Q . Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma. Am J Cancer Res. 2019; 9(6):1235-1245. PMC: 6610059. View

Tumati V, Iyengar P . The current state of oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Dis. 2018; 10(Suppl 21):S2537-S2544. PMC: 6123193. DOI: 10.21037/jtd.2018.07.19. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Curran Jr W, Paulus R, Langer C, Komaki R, Lee J, Hauser S . Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011; 103(19):1452-60. PMC: 3186782. DOI: 10.1093/jnci/djr325. View

Rodrigues G, Macbeth F, Burmeister B, Kelly K, Bezjak A, Langer C . International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. Clin Lung Cancer. 2011; 13(3):225-35. DOI: 10.1016/j.cllc.2011.11.002. View

Qian H, Gao F, Wang H, Ma F . The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. BMC Cancer. 2014; 14:683. PMC: 4180325. DOI: 10.1186/1471-2407-14-683. View

10.

Su S, Li T, Lu B, Wang X, Li J, Chen M . Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China. Int J Radiat Oncol Biol Phys. 2015; 93(4):769-77. DOI: 10.1016/j.ijrobp.2015.08.012. View

11.

Scagliotti G, de Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S . Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20(21):4285-91. DOI: 10.1200/JCO.2002.02.068. View

12.

Su S, Hu Y, Ouyang W, Ma Z, Lu B, Li Q . The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy. Radiat Oncol. 2014; 9:290. PMC: 4278263. DOI: 10.1186/s13014-014-0290-7. View

13.

Li S, Zhu R, Li D, Li N, Zhu X . Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2018; 10(6):3701-3713. PMC: 6051782. DOI: 10.21037/jtd.2018.05.105. View

14.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

15.

Chen X, Zhang W, Luo L, Fu S, Cao D, Su S . Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non-small cell lung cancer. Cancer Med. 2024; 13(17):e70221. PMC: 11403300. DOI: 10.1002/cam4.70221. View

16.

Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K . KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Cancer Sci. 2019; 110(3):1012-1020. PMC: 6398876. DOI: 10.1111/cas.13932. View

17.

Fournel P, Robinet G, Thomas P, Souquet P, Lena H, Vergnenegre A . Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01.... J Clin Oncol. 2005; 23(25):5910-7. DOI: 10.1200/JCO.2005.03.070. View

18.

Bezjak A, Paulus R, Gaspar L, Timmerman R, Straube W, Ryan W . Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019; 37(15):1316-1325. PMC: 6524984. DOI: 10.1200/JCO.18.00622. View

19.

Etiz D, Marks L, Zhou S, Bentel G, Clough R, Hernando M . Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002; 53(4):835-46. DOI: 10.1016/s0360-3016(02)02814-6. View

20.

Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A . Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2009; 126(3):651-5. DOI: 10.1002/ijc.24746. View